DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers, $ API Reference Price

1 API Suppliers
1 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

29 Drugs in Development

29 Drugs in Development

DIGITAL CONTENT

33 NEWS #PharmaBuzz

media
33 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Reproxalap, Adx-102, 916056-79-6, Reproxalap [usan], Ns-2, Ald-102

Molecular Formula

C₁₂H₁₃ClN₂O

Molecular Weight

236.70 g/mol

InChI Key

GUHFUVLKYSQIOQ-UHFFFAOYSA-N

FDA UNII

F0GIZ22IJH

Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjgren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.

1 2D Structure

Reproxalap

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol

2.1.2 InChI

InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3

2.1.3 InChI Key

GUHFUVLKYSQIOQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O

2.2 Other Identifiers

2.2.1 UNII

F0GIZ22IJH

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Adx-102

2. Ald-102

3. Reproxalap

2.3.2 Depositor-Supplied Synonyms

1. Reproxalap

2. Adx-102

3. 916056-79-6

4. Reproxalap [usan]

5. Ns-2

6. Ald-102

7. F0giz22ijh

8. Reproxalap (usan)

9. Ns2

10. Reproxalap [inn]

11. Unii-f0giz22ijh

12. Adx102

13. Chembl4297210

14. Schembl12228833

15. Gtpl10613

16. Ex-a3715

17. Sb18931

18. Example 5 [wo2018039197a1]

19. Hy-107150

20. Cs-0027443

21. D11309

22. 2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol

23. 2-quinolinemethanol, 3-amino-6-chloro-alpha,alpha-dimethyl-

24. 2-quinolinemethanol, 3-amino-6-chloro-.alpha.,.alpha.-dimethyl-

2.4 Create Date

2007-06-18

3 Chemical and Physical Properties

Molecular Formula	C₁₂H₁₃ClN₂O
Molecular Weight	236.70 g/mol
XLogP3	2.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Exact Mass	236.0716407 g/mol
Monoisotopic Mass	236.0716407 g/mol
Topological Polar Surface Area	59.1 Å²
Heavy Atom Count	16
Formal Charge	0
Complexity	259
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 Mechanism of Action

Reproxalap inhibits Reactive Aldehyde Species (RASP) and is being investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjgren-Larsson syndrome.

API SUPPLIERS